• Balsalazide Disodium Dihydrate: Precision Colonic Delivery f

  2026-07-16

  Balsalazide disodium is a water-soluble anti-inflammatory agent and prodrug of 5-aminosalicylic acid, optimized for site-specific activation in the colon. Its mechanism and dosing are validated in ulcerative colitis models and radiotracer workflows, with robust benchmarks for both efficacy and imaging applications.

• Ricin-Induced Bystander Necroptosis in Lung Epithelium: Mech

  2026-07-16

  This study elucidates how ricin toxin triggers bystander necroptosis in lung epithelial cells via inflammatory mediators released from monocytic cells. The findings redefine our understanding of toxin-mediated lung injury and highlight the complex interplay between cell death pathways during severe pulmonary inflammation.

• Refining In Vitro Drug Response Assessment in Cancer Researc

  2026-07-15

  Schwartz’s dissertation introduces a robust distinction between proliferative arrest and cell death metrics in in vitro anti-cancer drug evaluation. By clarifying these measurements, the study offers a more nuanced understanding of drug action mechanisms, improving experimental design and interpretation in cancer research.

• Streptavidin – Cy5: Advancing Biotin Detection in Apoptosis

  2026-07-15

  Streptavidin – Cy5 from APExBIO empowers ultrasensitive, multi-modal detection of biotinylated targets in apoptosis and cancer signaling studies. Its robust fluorescence and high-affinity biotin binding streamline advanced immunohistochemistry and flow cytometry protocols, setting a new standard for reproducibility and signal clarity.

• USP7 Modulates Macrophage Polarization via PKM2 in Acute Pan

  2026-07-14

  This study uncovers how ubiquitin-specific protease 7 (USP7) drives pro-inflammatory macrophage polarization in severe acute pancreatitis (SAP) through pyruvate kinase M2 (PKM2)-mediated metabolic reprogramming. The findings reveal a critical USP7–PKM2 axis that shapes immune responses in SAP, suggesting new therapeutic targets for inflammation modulation.

• AICAR in Action: Protocols and Innovations for AMPK Research

  2026-07-14

  AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) empowers metabolic disease and inflammation research by enabling precise AMPK pathway activation. This guide delivers step-by-step workflows, troubleshooting strategies, and the translational impact of new reference breakthroughs for robust, reproducible results.

• KR-12 Human Antimicrobial Peptide: Anti-Inflammatory Effects

  2026-07-13

  This study demonstrates that the KR-12 fragment of human cathelicidin exhibits significant anti-inflammatory and antibacterial effects in mouse models of colitis. The findings highlight KR-12's potential as a targeted therapeutic candidate for inflammatory bowel diseases, with mechanistic and translational insights relevant for advanced research.

• 15-PGDH Inhibition Enhances Muscle Repair in GLP-1RA Weight

  2026-07-13

  The reference study identifies inhibition of the prostaglandin-degrading enzyme 15-PGDH as a strategy to preserve and restore skeletal muscle mass and function during GLP-1 receptor agonist–induced weight loss. These findings suggest 15-PGDH inhibition can synergize with metabolic therapies to improve muscle regeneration without compromising the metabolic benefits of anti-obesity drugs.

• Caspase-3 Colorimetric Assay Kit: Practical Workflow Guidanc

  2026-07-12

  The Caspase-3 Colorimetric Assay Kit addresses the need for rapid, quantitative measurement of DEVD-dependent caspase-3 activity—a key biomarker in apoptosis and neurodegeneration research. This kit is best deployed in controlled laboratory settings where specificity for caspase-3 is required; it is not intended for non-apoptotic protease activity or for use in clinical diagnostics.

• Paroxetine Mesylate: Scenario-Driven Best Practices for Lab

  2026-07-10

  This article provides biomedical researchers and lab technicians with evidence-based guidance for using Paroxetine Mesylate (SKU C8698) in cell viability, proliferation, and cytotoxicity assays. Through five real-world laboratory scenarios, it demonstrates how this selective serotonin reuptake inhibitor addresses common workflow challenges, improves data reliability, and offers multi-target advantages validated by quantitative literature. Practical protocol recommendations and product selection tips empower scientists to maximize experimental reproducibility with Paroxetine Mesylate.

• Light-Inducible RNA-Releasing Proteins for Regulated Gene Th

  2026-07-09

  A recent study introduces a rationally engineered light-inducible RNA-releasing protein (LIRP) that enables precise, reversible translational regulation in mammalian cells. This innovation provides a versatile optogenetic gene switch, enhancing the safety and temporal control of gene therapies for chronic metabolic and retinal diseases.

• Necrostatin-1: Advanced Insights into RIP1 Kinase Inhibition

  2026-07-09

  Explore how Necrostatin-1, a potent RIP1 kinase inhibitor, enables mechanistic dissection of necroptosis and informs cutting-edge assay design. This article delivers unique scientific depth on selective allosteric inhibition and the translational impact for tissue injury and cell death modeling.

• Anti-ROR1 Antibody: Next-Gen Tools for Translational Liver R

  2026-07-08

  Explore the mechanistic rationale, workflow integration, and translational potential of Anti-ROR1 Antibody (Zilovertamab) for researchers modeling Wnt5a-induced ROR1 signaling in cancer and toxin-induced liver injury. This article delivers evidence-driven guidance on application parameters, competitive positioning, and future outlooks, escalating beyond existing protocol guides to offer strategic insight for cross-domain innovation.

• Molecular Mechanisms of Paroxetine: Beyond Serotonin Reuptak

  2026-07-08

  This review dissects the multifaceted molecular actions of paroxetine, revealing its primary role as a selective serotonin reuptake inhibitor (SSRI) and its engagement with additional molecular targets. The findings expand the understanding of paroxetine’s pharmacodynamics, offering insight into its clinical efficacy, off-label uses, and emerging translational applications.

• Sorafenib (BAY-43-9006): Mechanistic Insights and Precision

  2026-07-07

  Explore the scientifically rigorous mechanism of action and advanced research applications of Sorafenib (BAY-43-9006) as a multikinase inhibitor in cancer biology research. This article uniquely unpacks the compound's precision targeting, experimental design implications, and new evidence from ATRX-deficient tumor models.

11411 records 1/761 page Next 12345 下5页 Last page